logo

For the Inventor, By the Inventor

Redwood City, CA, United States of America

Biomea Fusion, Inc.


USPTO Granted Patents = 12


Trademarks = 4

Forward Citations = 22

Loading Chart...
Loading Chart...

43 inventors (with patents filed for the assignee):

goldMedal Thomas Butler (11 out of 24 patents)

silverMedal Jim Palmer (7 out of 7 patents)

bronzeMedal Ravi Upasani (7 out of 10 patents)

4.  Matthew Welsch (7 out of 12 patents)

5.  Edward Painter (7 out of 7 patents)

6.  Sridhar Vempati (7 out of 8 patents)

7.  Brendan Kelly (7 out of 7 patents)

8.  James T Palmer (5 out of 6 patents)

9.  Nan-Horng Lin (3 out of 43 patents)

10.  Thorsten A Kirschberg (3 out of 44 patents)

11.  Yongli Su (2 out of 8 patents)

12.  Xiaodong Wang (2 out of 24 patents)

13.  Ravindra B Upasani (2 out of 9 patents)

14.  Thu Phan (2 out of 15 patents)

15.  Solomon B Ungashe (2 out of 2 patents)


12 patents:

1. 12617783 - Heterocyclic GLP-1R agonists (2026-05-05),
2. 12275739 - Inhibitors of menin-MLL interaction (2025-04-14),
3. 12251385 - Covalent inhibitors of menin-MLL interaction for diabetes mellitus (2025-03-18),
4. 12215113 - Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide] (2025-02-04),
5. 12116371 - Substituted pyridines as irreversible inhibitors of menin-MLL interaction (2024-10-15),
6. 12077544 - Irreversible inhibitors of menin-MLL interaction (2024-09-03),
7. 12018032 - Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction (2024-06-25),
8. 11945785 - Pyrazine compounds as inhibitors of FLT3 (2024-04-02),
9. 11845753 - Inhibitors of menin-mll interaction (2023-12-19),
10. 11702421 - Substituted pyridines as irreversible inhibitors of menin-MLL interaction (2023-07-18),
11. 11174263 - Inhibitors of menin-MLL interaction (2021-11-16),
12. 11084825 - Substituted pyridines as irreversible inhibitors of menin-MLL interaction (2021-08-10),
Company Overview
Biomea Fusion, Inc. is a biotechnology company based in Redwood City, California, focused on developing innovative therapies for cancer treatment. The company specializes in precision medicine, leveraging advanced drug discovery techniques to create targeted therapies that address specific genetic mutations in tumors. With a commitment to improving patient outcomes, Biomea Fusion aims to transform the landscape of cancer care through its cutting-edge research and development efforts.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

12 Patents

#138 in Redwood City, CA

#6,066 in California

#25,578 in US

#48,209 in the World

Redwood City, CA (US)
Redwood City, CA, United States of America

Biomea Fusion, Inc.

Forward Citations = 22

43 inventors:

goldMedal Thomas Butler (11 out of 24 patents)

silverMedal Jim Palmer (7 out of 7 patents)

bronzeMedal Ravi Upasani (7 out of 10 patents)

4.  Matthew Welsch (7 out of 12 patents)

5.  Edward Painter (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biomea Fusion, Inc.. Retrieved from https://idiyas.com/company/biomea-fusion

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…